Ana Paula de Faria

Ana Paula de Faria

Auto-generated profile, based on publicly available information

Ana Paula de Faria

Laboratory of Cardiovascular Pharmacology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Integrated Blood Pressure Control
Verified
Journal Article
Open access
PDF file
MPMariana R. Pioli
Mariana R. Pioli
ARAlessandra M. V. Ritter
Alessandra M. V. Ritter
AFAna Paula de Faria
Ana Paula de Faria
RMRodrigo Modolo
Rodrigo Modolo
Hypertension is closely linked to increased cardiovascular risk and development of target organ damage (TOD). Therefore, proper clinical follow-up and treatment of hypertensive subjects are mandatory. A great number of individuals present a variation on blood pressure (BP) levels when they are assessed either in the office or in the out-of-office settings. This phenomenon is defined as white coat syndrome – a change in BP levels due to the presence of a physician or other health professional. In this context, the term “white coat syndrome” may refer to three important and different clinical conditions: 1) white coat hypertension, 2) white coat effect, and 3) masked hypertension. The development of TOD and the increased cardiovascular risk play different roles in these specific subgroups of white coat syndrome. Correct diagnose and clinical guidance are essential to improve the prognosis of these patients. The aim of this review was to elucidate contemporary aspects of these types of white coat syndrome on general and hypertensive population.

1 August 2020 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
NPNayara Fraccari Pires
Nayara Fraccari Pires
Helio Coelho-JuniorHelio Coelho-Junior
Helio Coelho-Junior
BGBruno Bavaresco Gambassi
Bruno Bavaresco Gambassi
AFAna Paula Cabral de Faria
Ana Paula Cabral de Faria
ARAlessandra Mileni Versuti Ritter
Alessandra Mileni Versuti Ritter
HMHeitor Moreno
Heitor Moreno
Aim. The present study compared the acute effects of aerobic (AER), resistance (RES), and combined (COM) exercises on blood pressure (BP) levels in people with resistant hypertension (RH) and nonresistant hypertension (NON-RH).Methods. Twenty patients (10 RH and 10 NON-RH) were recruited and randomly performed three exercise sessions and a control session. Ambulatory BP was monitored over 24 hours after each experimental session.Results. Significant reductions on ambulatory BP were found in people with RH after AER, RES, and COM sessions. Notably, ambulatory BP was reduced during awake-time and night-time periods after COM. On the other hand, the effects of AER were more prominent during awake periods, while RES caused greater reductions during the night-time period. In NON-RH, only RES acutely reduced systolic BP, while diastolic BP was reduced after all exercise sessions. However, the longest postexercise ambulatory hypotension was observed after AER (~11 h) in comparison to RES (~8 h) and COM (~4 h) exercises.Conclusion. Findings of the present study indicate that AER, RES, and COM exercises elicit systolic and diastolic postexercise ambulatory hypotension in RH patients. Notably, longer hypotension periods were observed after COM exercise. In addition, NON-RH and RH people showed different changes on BP after exercise sessions, suggesting that postexercise hypotension is influenced by the pathophysiological bases of hypertension.

5 May 2018 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
BMBeatriz Moreno
Beatriz Moreno
AFAna Paula de Faria
Ana Paula de Faria
ARAlessandra Mileni Versuti Ritter
Alessandra Mileni Versuti Ritter
LYLara Buonalumi Tacito Yugar
Lara Buonalumi Tacito Yugar
SFSilvia Elaine Ferreira‐Melo
Silvia Elaine Ferreira‐Melo
HMHeitor Moreno
Heitor Moreno
This study aimed to evaluate the effects of glycated hemoglobin (HbA1c) on flow‐mediated dilation, intima‐media thickness, pulse wave velocity, and left ventricular mass index in patients with resistant hypertension (RHTN) comparing RHTN–controlled diabetes mellitus and RHTN–uncontrolled type 2 diabetes mellitus. Two groups were formed: HbA1c <7.0% (RHTN–controlled diabetes mellitus: n = 98) and HbA1c ≥7.0% (RHTN–uncontrolled diabetes mellitus: n = 122). Intima‐media thickness and flow‐mediated dilation were measured by high‐resolution ultrasound, left ventricular mass index by echocardiography, and arterial stiffness by carotid‐femoral pulse wave velocity. No differences in blood pressure levels were found between the groups but body mass index was higher in patients with RHTN–uncontrolled diabetes mellitus. Endothelial dysfunction and arterial stiffness were worse in patients with RHTN–uncontrolled diabetes mellitus. Intima‐media thickness and left ventricular mass index measurements were similar between the groups. After adjustments, multiple linear regression analyses showed that HbA1c was an independent predictor of flow‐mediated dilation and pulse wave velocity in all patients with RHTN. In conclusion, HbA1c may predict the grade of arterial stiffness and endothelial dysfunction in patients with RHTN, and superimposed uncontrolled diabetes mellitus implicates further impairment of vascular function.

4 September 2014 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
AFAna Paula de Faria
Ana Paula de Faria
RMRodrigo Modolo
Rodrigo Modolo
VFVanessa Fontana
Vanessa Fontana
HMHeitor Moreno
Heitor Moreno

1 October 2017 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
JYJuan Carlos Yugar-Toledo
Juan Carlos Yugar-Toledo
RMRodrigo Modolo
Rodrigo Modolo
AFAna Paula de Faria
Ana Paula de Faria
HMHeitor Moreno
Heitor Moreno
Mineralocorticoid-receptor antagonists (MRAs) have proven to be effective in some types of hypertension, especially in resistant hypertension (RHTN). In this phenotype of hypertension, the renin–angiotensin–aldosterone pathway plays an important role, with MRAs being especially effective in reducing blood pressure. In this review, we show the relevance of aldosterone in RHTN, as well as some clinical characteristics of this condition and the main concepts involving its pathophysiology and cardiovascular damage. We analyzed the mechanisms of action and clinical effects of two current MRAs – spironolactone and eplerenone – both of which are useful in RHTN, with special attention to the former. RHTN represents a significant minority (10%–15%) of hypertension cases. However, primary-care physicians, cardiologists, nephrologists, neurologists, and geriatricians face this health problem on a daily basis. MRAs are likely one of the best pharmacological options in RHTN patients; however, they are still underused.

26 November 2019 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
MPMariana Rodrigues Pioli
Mariana Rodrigues Pioli
AFAna Paula de Faria
Ana Paula de Faria